- Home
- OMF vs NUVL Comparison
OMF vs NUVL Comparison
Compare OMF & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMF
- NUVL
- Stock Information
- Founded
- OMF 1920
- NUVL 2017
- Country
- OMF United States
- NUVL United States
- Employees
- OMF N/A
- NUVL N/A
- Industry
- OMF Finance: Consumer Services
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- OMF Finance
- NUVL Health Care
- Exchange
- OMF Nasdaq
- NUVL Nasdaq
- Market Cap
- OMF 6.2B
- NUVL 5.6B
- IPO Year
- OMF 2013
- NUVL 2021
- Fundamental
- Price
- OMF $51.82
- NUVL $74.61
- Analyst Decision
- OMF Buy
- NUVL Strong Buy
- Analyst Count
- OMF 11
- NUVL 8
- Target Price
- OMF $57.40
- NUVL $115.50
- AVG Volume (30 Days)
- OMF 977.5K
- NUVL 548.5K
- Earning Date
- OMF 04-29-2025
- NUVL 05-08-2025
- Dividend Yield
- OMF 8.03%
- NUVL N/A
- EPS Growth
- OMF N/A
- NUVL N/A
- EPS
- OMF 4.73
- NUVL N/A
- Revenue
- OMF $2,583,000,000.00
- NUVL N/A
- Revenue This Year
- OMF $74.73
- NUVL N/A
- Revenue Next Year
- OMF $7.68
- NUVL N/A
- P/E Ratio
- OMF $10.96
- NUVL N/A
- Revenue Growth
- OMF 0.94
- NUVL N/A
- 52 Week Low
- OMF $38.00
- NUVL $55.54
- 52 Week High
- OMF $58.90
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- OMF 56.83
- NUVL 54.31
- Support Level
- OMF $48.79
- NUVL $70.25
- Resistance Level
- OMF $52.71
- NUVL $75.97
- Average True Range (ATR)
- OMF 1.14
- NUVL 3.09
- MACD
- OMF 0.03
- NUVL 0.13
- Stochastic Oscillator
- OMF 75.37
- NUVL 79.92
About OMF OneMain Holdings Inc.
OneMain Holdings Inc is a consumer finance company providing loan products to customers through its branch network and the internet. The company provides personal loan products; offers credit cards; offers optional credit insurance and others; offers a customer-focused financial wellness program, and acquisitions and dispositions of assets and businesses. It provides origination, underwriting, and servicing of personal loans to non-prime customers. The company's reportable segment is Consumer and Insurance. The main source of revenue is net interest income.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.